ArriVent wows investors with promising China-developed lung cancer treatment
The drug startup’s shares rose 11% on their first trading day, after it raised $150 million in an upsized IPO underwritten by three major investment banks Key Takeaways: ArriVent raised…
Recent Articles
RELATED ARTICLES
-
CHINA BULLETIN: Local Governments Crushed by Debt
- CHINA BULLETIN: China Eases Up on Cross-Border Data Requirements
- CHINA BULLETIN: China-U.S. Rapprochement Continues with Xi-Biden Call, Yellen Visit
- CHINA BULLETIN: China Further Extends Its Welcome Mat for Foreign Investors
- CHINA BULLETIN: Bring on the Equipment Upgrades, Says Beijing
- CHINA BULLETIN: Economic Growth Target Stays at 5%
- CHINA BULLETIN: Foreign Investor Flight
